Catherine C. Coombs, MD, UNC School of Medicine
Advertisement
Articles by Catherine C. Coombs, MD, UNC School of Medicine
Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLPublished: January 8th 2021 | Updated:
Allogeneic Transplantation for CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment: Addressing Unmet NeedsPublished: January 8th 2021 | Updated:
Selecting Frontline Therapy to Treat CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment With Fixed-Duration RegimensPublished: January 8th 2021 | Updated:
Minimal Residual Disease in CLLPublished: January 8th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5